Clinical Trial Update: A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This Phase 1 trial studied how radiolabeled eribulin is metabolized and eliminated in patients with advanced solid tumors; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Eribulin (eribulin mesilate)

Snippet

Sponsor: Eisai Inc. | Conditions: Advanced Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2012-01-27